Calliditas Therapeutics AB

Biotech valuations and funding availability went into reverse in the second half of 2021, following a period of abundant financing. Meanwhile, big pharma companies face their own problems, with many b

In the space of only a few years, immunoglobulin A nephropathy (IgAN) has gone from no drug therapies available to three options on a list that is growing. The questions that remain now are how to seg

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Kaken Obtains Aadi’s Fyarro, Comm

The pharmaceutical, biotech and other allied industries came together in London on 4 December to celebrate another year of exceptional achievement at the 20th Annual Scrip Awards at the Raffles hotel